These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 38746089)

  • 61. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
    Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
    Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway.
    Chen C; Cheng CD; Wu H; Wang ZW; Wang L; Jiang ZR; Wang AL; Hu C; Dong YF; Niu WX; Qi S; Qi ZP; Liu J; Wang WC; Niu CS; Liu QS
    Acta Pharmacol Sin; 2021 Jan; 42(1):108-114. PubMed ID: 32398685
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma.
    Festuccia C; Mancini A; Colapietro A; Gravina GL; Vitale F; Marampon F; Delle Monache S; Pompili S; Cristiano L; Vetuschi A; Tombolini V; Chen Y; Mehrling T
    J Hematol Oncol; 2018 Feb; 11(1):32. PubMed ID: 29486795
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A novel strategy to increase the therapeutic potency of GBM chemotherapy via altering parenchymal/cerebral spinal fluid clearance rate.
    Umlauf BJ; Frampton G; Cooper A; Greene HF
    J Control Release; 2023 Dec; 364():195-205. PubMed ID: 37865172
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Dual blockade of EGFR and PI3K signaling pathways offers a therapeutic strategy for glioblastoma.
    Guo T; Wu C; Zhang J; Yu J; Li G; Jiang H; Zhang X; Yu R; Liu X
    Cell Commun Signal; 2023 Dec; 21(1):363. PubMed ID: 38115126
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Mechanistic Target of Rapamycin (mTOR) Inhibition Synergizes with Reduced Internal Ribosome Entry Site (IRES)-mediated Translation of Cyclin D1 and c-MYC mRNAs to Treat Glioblastoma.
    Holmes B; Lee J; Landon KA; Benavides-Serrato A; Bashir T; Jung ME; Lichtenstein A; Gera J
    J Biol Chem; 2016 Jul; 291(27):14146-14159. PubMed ID: 27226604
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Targeted nano-delivery of chemotherapy via intranasal route suppresses in vivo glioblastoma growth and prolongs survival in the intracranial mouse model.
    Sandbhor P; Goda J; Mohanty B; Gera P; Yadav S; Chekuri G; Chaudhari P; Dutt S; Banerjee R
    Drug Deliv Transl Res; 2023 Feb; 13(2):608-626. PubMed ID: 36245060
    [TBL] [Abstract][Full Text] [Related]  

  • 69. FoxM1 Promotes Stemness and Radio-Resistance of Glioblastoma by Regulating the Master Stem Cell Regulator Sox2.
    Lee Y; Kim KH; Kim DG; Cho HJ; Kim Y; Rheey J; Shin K; Seo YJ; Choi YS; Lee JI; Lee J; Joo KM; Nam DH
    PLoS One; 2015; 10(10):e0137703. PubMed ID: 26444992
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma.
    Cruickshanks N; Zhang Y; Hine S; Gibert M; Yuan F; Oxford M; Grello C; Pahuski M; Dube C; Guessous F; Wang B; Deveau C; Saoud K; Gallagher I; Wulfkuhle J; Schiff D; Phan S; Petricoin E; Abounader R
    Clin Cancer Res; 2019 Jan; 25(2):663-673. PubMed ID: 30201763
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Activation of JNK and p38 MAPK Mediated by ZDHHC17 Drives Glioblastoma Multiforme Development and Malignant Progression.
    Chen X; Hao A; Li X; Ye K; Zhao C; Yang H; Ma H; Hu L; Zhao Z; Hu L; Ye F; Sun Q; Zhang H; Wang H; Yao X; Fang Z
    Theranostics; 2020; 10(3):998-1015. PubMed ID: 31938047
    [No Abstract]   [Full Text] [Related]  

  • 72. MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma.
    Wu S; Wang S; Zheng S; Verhaak R; Koul D; Yung WK
    Mol Cancer Ther; 2016 Jul; 15(7):1656-68. PubMed ID: 27196759
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A Preclinical Investigation of GBM-N019 as a Potential Inhibitor of Glioblastoma via Exosomal mTOR/CDK6/STAT3 Signaling.
    Wu ATH; Huang HS; Wen YT; Lawal B; Mokgautsi N; Huynh TT; Hsiao M; Wei L
    Cells; 2021 Sep; 10(9):. PubMed ID: 34572040
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
    Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Identification of a Dexamethasone Mediated Radioprotection Mechanism Reveals New Therapeutic Vulnerabilities in Glioblastoma.
    Aldaz P; Auzmendi-Iriarte J; Durántez M; Lasheras-Otero I; Carrasco-Garcia E; Zelaya MV; Bragado L; Olías-Arjona A; Egaña L; Samprón N; Morilla I; Redondo-Muñoz M; Rico M; Squatrito M; Maria-Alonso M; Fernández-Irigoyen J; Santamaria E; Larráyoz IM; Wellbrock C; Matheu A; Arozarena I
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33478100
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Defining the role of mTOR pathway in the regulation of stem cells of glioblastoma.
    Jhanwar-Uniyal M; Gellerson O; Bree J; Das M; Kleinman G; Gandhi CD
    Adv Biol Regul; 2023 May; 88():100946. PubMed ID: 36658088
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo.
    Onken J; Torka R; Korsing S; Radke J; Krementeskaia I; Nieminen M; Bai X; Ullrich A; Heppner F; Vajkoczy P
    Oncotarget; 2016 Mar; 7(9):9876-89. PubMed ID: 26848524
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cadherin-3 is a novel oncogenic biomarker with prognostic value in glioblastoma.
    Martins EP; Gonçalves CS; Pojo M; Carvalho R; Ribeiro AS; Miranda-Gonçalves V; Taipa R; Pardal F; Pinto AA; Custódia C; Faria CC; Baltazar F; Sousa N; Paredes J; Costa BM
    Mol Oncol; 2022 Jul; 16(14):2611-2631. PubMed ID: 34919784
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Intracranial AAV-sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma.
    Crommentuijn MH; Maguire CA; Niers JM; Vandertop WP; Badr CE; Würdinger T; Tannous BA
    Mol Oncol; 2016 Apr; 10(4):625-34. PubMed ID: 26708508
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The HIF1α-PDGFD-PDGFRα axis controls glioblastoma growth at normoxia/mild-hypoxia and confers sensitivity to targeted therapy by echinomycin.
    Peng G; Wang Y; Ge P; Bailey C; Zhang P; Zhang D; Meng Z; Qi C; Chen Q; Chen J; Niu J; Zheng P; Liu Y; Liu Y
    J Exp Clin Cancer Res; 2021 Sep; 40(1):278. PubMed ID: 34470658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.